Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

Submitted by CP Staff on June 29, 2018 - 10:25am

Source:

Endpoints

News Tags:

Dermira

FDA

glycopyrronium

Qbrexza

excessive sweating

Headline:

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

snippet:

After a catastrophic failure in acne that obliterated its stock just months ago, Dermira $DERM had some redeeming news this morning — the FDA has OK’ed its anti-sweating drug glycopyrronium.

Search form

You are here

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb

Acne was a bust, but excessive sweating scores FDA OK for Dermira — shares climb